PharmAthene, Inc.

Nov 12, 09
	NEW STORY
08:59 ET	PharmAthene Reports Third Quarter 2009 Financial and Operational Results
Oct 05, 09
08:30 ET	PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
Sep 23, 09
09:06 ET	PharmAthene to Present at The Maxim Group Growth Conference September 29, 2009
Sep 03, 09
08:54 ET	PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
Sep 01, 09
09:00 ET	PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
Aug 17, 09
09:00 ET	PharmAthene Strengthens Senior Management Team; Appoints Charles A. Reinhart III Senior Vice President, Chief Financial Officer
Aug 13, 09
08:30 ET	PharmAthene Reports Second Quarter 2009 Financial and Operational Results
Aug 06, 09
10:22 ET	PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
Jul 31, 09
08:30 ET	PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
Jul 27, 09
09:00 ET	PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
Jul 09, 09
14:11 ET	PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
Jun 02, 09
08:30 ET	PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
May 22, 09
11:13 ET	PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
May 15, 09
08:30 ET	PharmAthene Reports First Quarter 2009 Financial and Operational Results
May 08, 09
08:30 ET	PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
Apr 28, 09
08:46 ET	PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
Mar 31, 09
09:00 ET	Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
Mar 30, 09
16:00 ET	PharmAthene Reports Year End 2008 Financial Results
Mar 24, 09
09:26 ET	PharmAthene Announces $5.5 Million Public Equity Offering
Feb 24, 09
09:00 ET	PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Nov 19, 08
10:00 ET	PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
Nov 13, 08
16:01 ET	Pharmathene Reports Third Quarter 2008 Financial and Operational Results
Nov 04, 08
09:00 ET	PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
Oct 27, 08
15:21 ET	PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
Oct 23, 08
16:37 ET	PharmAthene to Present at the 7th Annual BIO Investor Forum in San Francisco
Oct 15, 08
09:00 ET	PharmAthene Announces $1.6 Million Congressional Appropriation for Continued Development of Protexia(R)
Oct 13, 08
09:00 ET	PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
Sep 30, 08
16:01 ET	PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
Sep 26, 08
10:20 ET	PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
Sep 24, 08
09:00 ET	PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Sep 18, 08
11:20 ET	PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
Sep 16, 08
10:52 ET	PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
Sep 15, 08
12:11 ET	PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
Aug 12, 08
16:00 ET	PharmAthene Reports Second Quarter 2008 Financial and Operational Results
Aug 11, 08
11:02 ET	Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
Aug 05, 08
09:00 ET	PharmAthene to Host Second Quarter 2008 Conference Call and Webcast on Tuesday, August 12, 2008
Jul 31, 08
15:05 ET	PharmAthene Submits Response to DHHS Request for Proposals for SparVax(TM) - A Recombinant Protective Antigen Vaccine
Jul 10, 08
09:00 ET	PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
Jun 11, 08
14:41 ET	PharmAthene CEO Participates on Panel at the 6th Annual Biodefense Vaccines & Therapeutics Conference in Washington DC
May 13, 08
16:00 ET	PharmAthene Reports First Quarter 2008 Financial Results
May 06, 08
16:31 ET	PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
Apr 09, 08
09:16 ET	PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimer's Disease
Apr 02, 08
13:16 ET	PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
Mar 31, 08
16:00 ET	PharmAthene Reports Year-End 2007 Financial Results
Mar 26, 08
08:30 ET	Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthene's Protexia(R) Program
Mar 24, 08
15:57 ET	PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Mar 20, 08
16:24 ET	PharmAthene to Delay Release of Full Year 2007 Financial Results
13:25 ET	PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
Mar 13, 08
09:52 ET	PharmAthene to Host Year-End 2007 Earnings Conference Call and Webcast on Thursday, March 20, 2008
Mar 10, 08
11:34 ET	PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
Mar 06, 08
08:30 ET	PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
Feb 08, 08
09:00 ET	PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
Feb 06, 08
11:54 ET	PharmAthene to Present at the BIO CEO & Investor Conference 2008
Jan 16, 08
16:48 ET	Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthene's Legal Action in Breach of Contract Lawsuit Against SIGA
Nov 13, 07
16:00 ET	PharmAthene Reports Third Quarter 2007 Financial Results
Nov 06, 07
09:00 ET	PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
07:00 ET	PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
Oct 30, 07
18:00 ET	PharmAthene to Present at the Rodman and Renshaw/Acumen BioFin 9th Annual Healthcare Conference
Sep 24, 07
08:44 ET	PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
Aug 15, 07
08:58 ET	Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Aug 13, 07
15:54 ET	Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Aug 07, 07
14:32 ET	PharmAthene Common Shares and Warrants to Resume Trading on the American Stock Exchange
Jul 19, 07
15:58 ET	Healthcare Acquisition Corp. Announces Special Meeting of Stockholders to Vote on Proposed Merger With PharmAthene and Announces Mailing of Proxies to Stockholders of Record
Apr 03, 07
08:00 ET	PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research
Mar 30, 07
10:00 ET	Anthrax Monoclonal Antibody Valortim(TM) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection
Jan 22, 07
07:00 ET	PharmAthene and Healthcare Acquisition Corp. Announce Definitive Merger Agreement
Jan 08, 07
08:30 ET	PharmAthene Enhances Executive Leadership Team and Appoints Christopher C. Camut Vice President and Chief Financial Officer
Nov 06, 06
09:14 ET	PharmAthene Receives Tech Company of the Year Award from Anne Arundel Tech Council
Oct 18, 06
09:00 ET	PharmAthene Awarded $1.7 Million NIH Grant for Protexia(R)
Sep 25, 06
16:01 ET	PharmAthene Awarded $213 Million Department of Defense Contract for Advanced Development of Protexia(R)
Jun 12, 06
10:15 ET	PharmAthene Presents Data on Recombinant Human Butyrylcholinesterase Program at Bioscience Review 2006
Dec 14, 05
08:31 ET	Strategic Biodefense Platform Earns PharmAthene Anne Arundel Technology Council 'Innovator of the Year' Award
Mar 10, 05
09:02 ET	PharmAthene Adds Premier Chemical Scavenger Franchise to its Leading Biological and Chemical Defense Portfolio
Oct 12, 04
09:14 ET	PharmAthene, Inc. Closes $50 Million in Series B Financing
Mar 31, 04
10:43 ET	PharmAthene Submits IND for ToxBlox(TM) to Treat Anthrax Infection
Feb 19, 04
09:25 ET	Developer of Anthrax Anti-Toxin Names New Management Team